Antitumor Activity of Resveratrol and its Sulfated Metabolites against Human Breast Cancer Cells

Abstract

Resveratrol (3,4′,5-trihydroxy-trans-stilbene) is a naturally occurring polyphenolic compound found in grapes, wine and medicinal plants with a variety of biological and pharmacological activities including pronounced anticancer properties. These effects are observed despite its extremely low bioavailability and rapid clearance from the circulation due to extensive sulfation and glucuronidation in the intestine and liver. In order to determine whether its metabolites demonstrate any cytotoxic properties, three major human sulfated conjugates of resveratrol were synthesized and their anticancer activity evaluated against three breast cancer cell lines (two hormone-dependent: MCF-7 and ZR-75-1; one hormone-independent: MDA‐MB‐231) and one immortalized breast epithelial cell line (MCF-10A). We found that, in contrast to resveratrol, all three sulfated metabolites were less potent against MCF-7, MDA‐MB‐231 and ZR-75-1 cells (trans-resveratrol 3-O-sulfate < trans-resveratrol 4′-O-sulfate < trans-resveratrol 3-O-4′-O-disulfate) indicating that any conjugation of the phenolic groups with sulfuric acid strongly affecting the cytotoxicity. Interestingly, all sulfated metabolites were reduced about 10-fold, but showed nearly equal cytotoxicity towards nonmalignant MCF-10A breast cells (IC_50 s: 202–228 µM). In summary, in contrast to resveratrol its sulfated metabolites showed poor cytotoxicity in human malignant and nonmalignant breast cancer cell lines. However, the in vitro activity of the metabolites may not necessarily reflect their in vivo function, given the fact that the ubiquitously existing human sulfatases could convert the metabolites back to resveratrol in humans.

Key words

resveratrol - 3,4′,5‐trihydroxy‐trans‐stilbene - metabolites - cytotoxicity - cancer cell lines

References

• 1 Burns J, Yokota T, Ashihara H, Lean M E, Crozier A. Plant foods and herbal sources of resveratrol.  J Agric Food Chem. 2002;  50 3337-3340
• 2 Vastano B C, Chen Y, Zhu N, Ho C T, Zhou Z, Rosen R T. Isolation and identification of stilbenes in two varieties of Polygonum cuspidatum.  J Agric Food Chem. 2000;  48 253-256
• 3 Frémont L, Belguendouz L, Delpal S. Antioxidant activity of resveratrol and alcohol-free wine polyphenols related to LDL oxidation and polyunsaturated fatty acids.  Life Sci. 1999;  64 2511-2521
• 4 Zou J G, Huang Y Z, Chen Q, Wei E H, Hsieh T C, Wu J M. Resveratrol inhibits copper ioninduced and azo compound-initiated oxidative modification of human low density lipoprotein.  Biochem Mol Biol Int. 1999;  47 1089-1096
• 5 Murias M, Handler N, Erker T, Pleban K, Ecker G, Saiko P, Szekeres T, Jäger W. Resveratrol analogues as selective cyclooxygenase-2 inhibitors: synthesis and structure-activity relationship.  Bioorg Med Chem. 2004;  12 5571-5578
• 6 Murias M, Jäger W, Handler N, Erker T, Horvath Z, Szekeres T, Nohl H, Gille L. Antioxidant, prooxidant and cytotoxic activity of hydroxylated resveratrol analogues: structure-activity relationship.  Biochem Pharmacol. 2005;  69 903-912
• 7 Jang M, Cai L, Udeani G O, Slowing K V, Thomas C F, Beecher C W, Fong H H, Famsworth N R, Kinghorn A D, Mehta R G, Moon R C, Pezzuto J M. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes.  Science. 1997;  275 218-220
• 8 Ragione F D, Cucciola V, Borriello A, Pietra V D, Racioppi L, Soldati G, Manna C, Galleti P, Zappia V. Resveratrol arrests the cell division cycle at S/G2 phase transition.  Biochem Biophys Res Commun. 1998;  250 53-58
• 9 Saiko P, Pemberger M, Horvath Z, Savinc I, Grusch M, Handler N, Erker T, Jaeger W, Fritzer-Szekeres M, Szekeres T. Novel resveratrol analogs induce apoptosis and cause cell cycle arrest in HT29 human colon cancer cells: inhibition of ribonucleotide reductase activity.  Oncol Rep. 2008;  19 1621-1626
• 10 Levi F, Pasche C, Lucchini F, Guidoni R, Ferrarono M, La V C. Resveratrol and breast cancer risk.  Eur J Cancer Prev. 2005;  14 139-142
• 11 Walle T, Hsieh F, DeLegge M H, Oatis Jr J E, Walle U K. High absorption but very low bioavailability of oral resveratrol in humans.  Drug Metab Dispos. 2004;  32 1377-1382
• 12 Burkon A, Somoza V. Quantification of free and protein-bound trans-resveratrol metabolites and identification of trans-resveratrol-C/O-conjugated diglucuronides – two novel resveratrol metabolites in human plasma.  Mol Nutr Food Res. 2008;  52 549-557
• 13 Marier J F, Vachon P, Gritsas A, Zhang J, Moreau J P, Ducharme M P. Metabolism and disposition of resveratrol in rats: extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model.  J Pharmacol Exp Ther. 2002;  302 369-373
• 14 Maier-Salamon A, Hagenauer B, Wirth M, Gabor F, Szekeres T, Jäger W. Increased transport of resveratrol across monolayers of the human intestinal Caco-2 cells is mediated by inhibition and saturation of metabolites.  Pharm Res. 2006;  23 2107-2115
• 15 Miksits M, Maier-Salamon A, Aust S, Thalhammer T, Reznicek G, Kunert O, Haslinger E, Szekeres T, Jaeger W. Sulfation of resveratrol in human liver: evidence of a major role for the sulfotransferases SULT1A1 and SULT1E1.  Xenobiotica. 2005;  35 1101-1119
• 16 Murias M, Miksits M, Aust S, Spatzenegger M, Thalhammer T, Szekeres T, Jaeger W. Metabolism of resveratrol in breast cancer cell lines: impact of sulfotransferase 1A1 expression on cell growth inhibition.  Cancer Lett. 2008;  261 172-182
• 17 Kawai N, Fujibayashi Y, Kuwabara S, Takao K, Ijuin Y, Kobayashi S. Synthesis of a potential key intermediate of akaterpin, specific inhibitor of PI‐PLC.  Tetrahedron. 2000;  56 6467-6478
• 18 Yu C, Shin Y G, Chow A, Li Y, Kosmeder J W, Lee Y S, Hirschelman W H, Pezzuto J M, Mehta R G, van Breemen R B. Human, rat, and mouse metabolism of resveratrol.  Pharm Res. 2002;  19 1907-1914
• 19 Wenzel E, Soldo T, Erbersdobler H, Somoza V. Bioactivity and metabolism of trans-resveratrol orally administered to Wistar rats.  Mol Nutr Food Res. 2005;  49 482-494
• 20 Worland P J, Kaur G, Stetler-Stevenson M, Sebers S, Sartor O, Sausville E A. Alteration of the phosphorylation state of p 34cdc2 kinase by the flavone L86-8275 in breast carcinoma cells. Correlation with decreased H1 kinase activity.  Biochem Pharmacol. 1993;  46 1831-1840
• 21 Carlson B A, Dubay M M, Sausville E A, Brizuela L, Worland P J. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells.  Cancer Res. 1996;  56 2973-2978
• 22 Wang L X, Heredia A, Song H, Zhang Z, Yu B, Davis C, Redfield R. Resveratrol glucuronides as the metabolites of resveratrol in humans: characterization, synthesis, and anti-HIV activity.  J Pharm Sci. 2004;  93 2448-2457
• 23 Pasqualini J R, Chetrite G S. Recent insight on the control of enzymes involved in estrogen formation and transformation in human breast cancer.  J Steroid Biochem Mol Biol. 2005;  93 221-236
• 24 Ghosh D. Human sulfatases: a structural perspective to catalysis.  Cell Mol Life Sci. 2007;  64 2013-2022
• 25 Utsumi T, Yoshimura N, Takeuchi S, Maruta M, Maeda K, Harada N. Elevated steroid sulfatase expression in breast cancers.  J Steroid Biochem Mol Biol. 2000;  73 141-145